Iktos
Generative AI and robotics for autonomous drug discovery, compressing the DMTA cycle to under two years.
Iktos is the rare platform that covers the entire DMTA loop—design, make, test, analyze—with both generative AI and robotics. It's ideal for well-funded pharma teams attacking hard targets like PROTACs and PPIs. The catch: pricing is contact-only and the hardware footprint is significant. If you only need retrosynthesis, Spaya alone is a lower-risk starting point.
Verified 5d ago · liveness 60/100 · cite: rightaichoice.com/tools/iktos
- Large pharma companies investing in full DMTA automation with AI and robotics
- Teams targeting hard targets like protein-protein interactions, molecular glues, or PROTACs
- Organizations aiming to compress discovery timelines to less than 2 years
- Chemistry groups that need generative design with proven synthetic accessibility
- Academic labs or small biotechs with limited capital for enterprise robotics
- Teams that only need retrosynthesis without automation (use Spaya standalone)
- Researchers focused on biologics, antibodies, or gene therapies
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Iktos if you're a small biotech or academic lab without the capital for enterprise robotics or if you only need retrosynthesis—Spaya alone is a lighter option.
Pricing is contact-only, so you won't know the cost until you engage sales; expect enterprise-level fees.
Iktos targets enterprises; pricing is custom and likely high. Cheaper alternatives for retrosynthesis include Spaya standalone, but for full DMTA automation, Iktos is a premium option.
In short
Iktos — Generative AI and robotics for autonomous drug discovery, compressing the DMTA cycle to under two years. Best for Large pharma companies investing in full DMTA automation with AI and robotics, Teams targeting hard targets like protein-protein interactions, molecular glues, or PROTACs, Organizations aiming to compress discovery timelines to less than 2 years. Contact Sales pricing.
Viability Score
How well maintained and how widely used is Iktos? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: September 2026
How we score →Key Features
- Generative AI for de novo drug design (Makya)
- Data analysis and visualization (Makya 2.0)
- Multi-parametric optimization with ML models
- 3D constraint inclusion in molecular design
- Synthetic accessibility optimization
- AI-driven retrosynthesis with real-time route display (Spaya)
- Customizable synthesis steps and constraints
- Integration with multiple data providers for retrosynthesis
- Automated synthesis and analysis (Iktos Robotics)
- Workflow management and raw material ordering
- High-throughput DMTA cycle automation
- Multidimensional biological data from imaging platform
- In-cellulo screening for protein and RNA interactions
- APIs for agentic workflows (Iktos Engine)
- Integration with Chemspeed robotic systems
About Iktos
Iktos combines generative AI with lab automation to compress the small-molecule drug discovery cycle. Built for pharma and biotech teams, its platform—Makya, Spaya, and Iktos Robotics—takes a compound from in-silico design to synthesis and testing. The goal: discovery timelines under two years, with a fully autonomous lab in sight. Makya is a generative AI SaaS platform for de novo drug design, emphasizing synthetic accessibility, multi-parametric optimization, and 3D constraints. The Makya 2.0 release adds a revamped data analysis and visualization experience, so chemists can prioritize compounds against all project objectives with confidence. Spaya is the retrosynthesis arm. It displays real-time synthetic routes that convert target molecules into commercially available starting materials, with customizable steps and constraints. It integrates with multiple data providers and is compatible with Iktos Robotics. Iktos Robotics automates the DMTA cycle—workflow management, raw material ordering, synthesis, purification, and analysis. Biology workflows extend this with in-cellulo screening and multidimensional imaging, targeting challenging targets like protein-protein interactions, RNA-protein interactions, molecular glues, and PROTACs. Recent additions include the Iktos Engine, a set of APIs for agentic workflows and computational chemistry pipelines, plus a partnership with Chemspeed to strengthen robotic integration. Since 2016, Iktos has run over 60 collaborations. That said, this is an enterprise-grade, hardware-heavy platform with contact-only pricing—best suited for large organizations ready to invest in lab infrastructure.
Behind the Verdict
Iktos stands out in the AI drug discovery space because it pushes beyond in silico design into the wet lab. Most competitors stop at generative chemistry; Iktos pairs that with robotics to close the loop. The Makya 2.0 update improves the data analysis experience, which is critical when you have dense experimental data flowing back into the design model. The partnership with Chemspeed and the Iktos Engine APIs show a commitment to making the platform programmatically accessible, which is good news for computational chemists. But the platform's strengths are also its constraints. It's designed for small-molecule discovery and is explicitly not for biologics. The hardware integration means you need lab infrastructure and capital. Pricing is contact-only, so it's not a tool you can try on a credit card. For a team just wanting retrosynthesis, Spaya alone might be overkill—but it's a reasonable standalone entry point. Where Iktos shines is in attacking hard targets—protein-protein interactions, RNA-protein interactions, PROTACs—where iterative design-make-test cycles can be accelerated. The in-cellulo screening gives biological context early, which is a differentiator. If you're a large pharma with the resources to invest in lab automation, Iktos is a serious candidate. For a smaller biotech, the cost and infrastructure may be prohibitive.
Researching Iktos? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas Iktos actually fits — and what changes day-one when you adopt it.
You need to design novel compounds with good synthetic accessibility and prioritize them.
Outcome: Use Makya's generative AI to propose candidates, review them with the new data analysis dashboard, and send top picks to Spaya for route planning.
You want to automate the design-make-test cycle for a challenging target like a PROTAC.
Outcome: Integrate Iktos Engine APIs to script the process, use Makya for molecular design and Spaya for retrosynthesis, then have Iktos Robotics execute synthesis and testing.
You're evaluating whether to invest in lab automation for drug discovery.
Outcome: Run a pilot with Iktos Robotics on a specific project to measure cycle-time reduction and assess the potential for a fully autonomous lab.
Use Cases
- Design novel, synthetically accessible drug candidates using generative AI and validate via automated synthesis
- Plan efficient retrosynthetic routes from target compound to starting materials with Spaya
- Automate the DMTA cycle for hit-to-lead and lead optimization with robotic synthesis and testing
- Identify small-molecule modulators for challenging targets like protein-protein interactions and PROTACs
Models Under the Hood
as of 2026-08-30
Limitations
- As a specialized drug discovery platform, Iktos integrates AI and robotics, but full automation depends on robotic hardware and may be limited by lab capabilities.
- Pricing is not publicly disclosed, likely requiring direct contact, and access to features like APIs may be contract-dependent.
- The platform focuses on small-molecule drug discovery, with limited applicability to biologics or clinical-stage development.
as of 2026-08-28
Verification history
We have re-verified Iktos 17 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — re-checked, vendor evidence unchanged
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Showing the 6 most recent of 17 verification passes.
Free to cite with attribution — this page re-verifies continuously.
Where the pricing makes sense
The company stage and team size where Iktos's pricing actually pencils out — and where peers do it cheaper.
Iktos targets enterprises; pricing is custom and likely high. Cheaper alternatives for retrosynthesis include Spaya standalone, but for full DMTA automation, Iktos is a premium option.
Setup time & first value
How long it actually takes to get something useful out of Iktos — broken out by persona, not the marketing-page minute.
For Makya and Spaya, expect a few weeks to get teams trained and integrated with existing data. For Iktos Robotics, setup can take months due to hardware installation and workflow calibration.
Switching to or from Iktos
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From manual design tools: Import your existing compound libraries and project data into Makya to start generative design quickly.
- ↗To other retrosynthesis tools like ChemDraw or Reaxys: You can export routes from Spaya and continue with your existing workflow.
Integrations
Resources & Guides
Tutorials & Learning
Official links
Tools that pair well with Iktos
Common stack mates teams adopt alongside Iktos, with the specific reason each pairing earns its keep.
Recursion
AI-native drug discovery: phenomics, robotics, and a 50+ petabyte dataset to de-risk medicines.
Insilico Medicine
End-to-end generative AI drug discovery platform from target ID to clinical trials, validated by a Phase III pipeline.
Evotec
Tech-driven drug discovery and biologics manufacturing platform
Alternatives to Iktos
View allRecursion
AI-native drug discovery: phenomics, robotics, and a 50+ petabyte dataset to de-risk medicines.
Insilico Medicine
End-to-end generative AI drug discovery platform from target ID to clinical trials, validated by a Phase III pipeline.
Frequently Asked Questions
Used Iktos? Help shape our editorial sentiment research.